Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Andromeda Biotech receives EMEA support for the clinical development plan of its lead product

Andromeda Biotech receives EMEA support for the clinical development plan of its lead product, DiaPep277, for the treatment of type 1 diabetes

Yavne, Israel, November 23rd, 2009: Andromeda Biotech Ltd. announces that the European Medicines Agency, (EMEA), accepts the clinical development plan for DiaPep 277, Andromeda’s lead product for the treatment of type 1 diabetes.

The plan submitted by Andromeda includes conducting a confirmatory Phase III study to support the results from the ongoing current Phase III study and will recruit 450 newly diagnosed adult patients (ages 20-45) with type 1 diabetes. About 100 medical centers worldwide, in North America, Europe, South America, and Israel are planned to participate. The goal of the study is to evaluate the long term safety and treatment effect of DiaPep277 to preserve secretion of insulin in diabetic patients. The study will be double blinded with one treatment group and a placebo group.

“With the support of the EMEA and following the completion of recruitment in the current ongoing Phase III clinical study, we are very encouraged and will be forging ahead with our clinical development plan in order to pave the way for the drug approval of DiaPep277,” said Dr. Shlomo Dagan, CEO of Andromeda.

Andromeda has also submitted the clinical development plan for the Phase III confirmatory study to the FDA for their approval.

The Phase III clinical study is scheduled to begin during the first half of 2010.

About Andromeda Biotech

Andromeda Biotech Ltd., a subsidiary of Clal Biotechnology Industries Ltd. (TASE: CBI), is focused on the development of an innovative treatment for autoimmune diabetes. Andromeda’s DiaPep277, currently in Phase III Clinical Studies, is a novel therapeutic approach in treating Type 1 diabetes. It is a unique peptide derived from the human protein, HSP60, which immunomodulates the immune system, prevents the destruction of pancreatic cells that secrete insulin and preserves their natural function.

To date, there is no therapy capable of preventing the destruction of insulin secreting beta cells. Initially, DiaPep277 is designed to treat newly diagnosed Type 1 diabetes adult patients with residual insulin secreting cells. Other potential target populations are Type 1 diabetic children, patients with high risk of Type 1 diabetes and Type 1 diabetes patients with slow progressing disease. Type I diabetes affects approximately 1% of the world’s population and the potential drug market for DiaPep277 is estimated by the company to be more than half a billion dollars per year.

For more information about Andromeda Biotech please visit our site: (

Media Contact:

Yamit Nissanov, PR for Andromeda Biotech, +972-9-9514666, +972-52-5541810,


Publisher Contact Information:

Andromeda Biotech

Company profile of Andromeda Biotech
Past press releases of Andromeda Biotech.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 4€3.3MNanotechnology
Dec 3€21.0MBusiness applications
Dec 2€7.0MDigital signal processing
Dec 2€7.4MBiotechnology
Nov 30€3.7MConsumer electronics
Nov 12€20.0MAgriculture related
Jan 17€13.0MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.